ArticleNature communications2023
Infant microbiome cultivation and metagenomic analysis reveal Bifidobacterium 2'-fucosyllactose utilization can be facilitated by coexisting species.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Bifidogenic Effect of 2'-Fucosyllactose (2'-FL) on the Gut Microbiome of Healthy Formula-Fed Infants: A Randomized Clinical Trial.Nutrients · 2025Trial
- Amino acid-based formula feeding is associated with increased risk ofGut microbes · 2026Article
- Orchestrating life's first community: molecular assembly by human milk oligosaccharides.Gut microbes · 2026Review
- Maternal obesity alters human milk oligosaccharides content and correlates with early acquisition of late colonizers in the neonatal gut microbiome.Gut microbes · 2026Article
- 2'-FL's Depiction of the Human Physiological Function Landscape.Food science & nutrition · 2026Review
- Bacteriocin gene-mediated ecological adaptation of Bifidobacterium breve in the adult human gut.Cell genomics · 2026Article
- bifidoAnnotator: fine-grained annotation of bifidobacterial glycoside hydrolases for human milk glycan utilization.Microbial genomics · 2026Article
- Infant gut microbiota coverage by different culture media.BMC microbiology · 2026Article
- Human DNA levels in feces reflect gut inflammation and associate with presence of gut species in IBD patients across the age spectrum.Microbiome · 2026Article
- Significant strain microdiversity in mother-infant dyad cohorts across ethnic groups reveals population specificity of bifidobacteria microbiota transmission.Frontiers in microbiology · 2026Article
- Human milk oligosaccharide metabolism and antibiotic resistance in early gut colonizers: insights from bifidobacteria and lactobacilli in the maternal-infant microbiome.Gut microbes · 2025Article
- Fecal gut microbiome alterations and its association with lactose intolerance in children with rotavirus infection-related diarrhea.European journal of pediatrics · 2025Article
- Maternal Milk Orchestrates the Development of Infant Gut Microbiota: Implications for Health and Future Research Directions.Research (Washington, D.C.) · 2025Review
- Primary succession of Bifidobacteria drives pathogen resistance in neonatal microbiota assembly.Nature microbiology · 2024Article
- Cross-feeding of bifidobacteria promotes intestinal homeostasis: a lifelong perspective on the host health.NPJ biofilms and microbiomes · 2024Review
- Enrichment and characterization of human-associated mucin-degrading microbial consortia by sequential passage.FEMS microbiology ecology · 2024Article
- Resource sharing of an infant gut microbiota synthetic community in combinations of human milk oligosaccharides.The ISME journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
The early-life gut microbiome development has long-term health impacts and can be influenced by factors such as infant diet. Human milk oligosaccharides (HMOs), an essential component of breast milk that can only be metabolized by some beneficial gut microorganisms, ensure proper gut microbiome establishment and infant development. However, how HMOs are metabolized by gut microbiomes is not fully elucidated. Isolate studies have revealed the genetic basis for HMO metabolism, but they exclude the possibility of HMO assimilation via synergistic interactions involving multiple organisms. Here, we investigate microbiome responses to 2'-fucosyllactose (2'FL), a prevalent HMO and a common infant formula additive, by establishing individualized microbiomes using fecal samples from three infants as the inocula. Bifidobacterium breve, a prominent member of infant microbiomes, typically cannot metabolize 2'FL. Using metagenomic data, we predict that extracellular fucosidases encoded by co-existing members such as Ruminococcus gnavus initiate 2'FL breakdown, thus critical for B. breve's growth. Using both targeted co-cultures and by supplementation of R. gnavus into one microbiome, we show that R. gnavus can promote extensive growth of B. breve through the release of lactose from 2'FL. Overall, microbiome cultivation combined with genome-resolved metagenomics demonstrates that HMO utilization can vary with an individual's microbiome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.